Exhibit 31

                                 CERTIFICATIONS

I, Judith Segall, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioTime, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the issuer as of,
and for, the periods presented in this report;

4. The issuer's other certifying officers and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rule 13a-14(c)) for the issuer and have:

      (a) Designed such disclosure controls and procedures to ensure that
      material information relating to the issuer, including its consolidated
      subsidiaries, is made known to us by others within those entities,
      particularly during the period in which the periodic reports are being
      prepared;

      (b) Evaluated the effectiveness of the issuer's disclosure controls and
      procedures as of a date within 90 days prior to the filing date of this
      quarterly report (the "Evaluation Date"); and

      (c) Presented in this report our conclusions about the effectiveness of
      the disclosure controls and procedures based on our evaluation as of the
      Evaluation Date;

5. The issuer's other certifying officers and I have disclosed, based on our
most recent evaluation, to the issuer's auditors and the audit committee of
issuer's board of directors (or persons performing the equivalent functions):

      (a) All significant deficiencies in the design or operation of internal
      controls which could adversely affect the issuer's ability to record,
      process, summarize and report financial data and have identified for the
      issuer's auditors any material weaknesses in internal controls; and

      (b) Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the issuer's internal controls;
      and

                                       1


6. The issuer's other certifying officers and I have indicated in this quarterly
report whether or not there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date:  August 13, 2004

      /s/ Judith Segall
      ------------------------------------
      Judith Segall
      Vice-President - Operations
      Member, Office of the President*

* The Office of the President is comprised of the three executive officers of
the issuer who collectively exercise the powers of the Chief Executive Officer

                                       2



                                 CERTIFICATIONS

I, Hal Sternberg, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioTime, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the issuer as of,
and for, the periods presented in this report;

4. The issuer's other certifying officers and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rule 13a-14(c)) for the issuer and have:

      (a) Designed such disclosure controls and procedures to ensure that
      material information relating to the issuer, including its consolidated
      subsidiaries, is made known to us by others within those entities,
      particularly during the period in which the periodic reports are being
      prepared;

      (b) Evaluated the effectiveness of the issuer's disclosure controls and
      procedures as of a date within 90 days prior to the filing date of this
      quarterly report (the "Evaluation Date"); and

      (c) Presented in this report our conclusions about the effectiveness of
      the disclosure controls and procedures based on our evaluation as of the
      Evaluation Date;

5. The issuer's other certifying officers and I have disclosed, based on our
most recent evaluation, to the issuer's auditors and the audit committee of
issuer's board of directors (or persons performing the equivalent functions):

      (a) All significant deficiencies in the design or operation of internal
      controls which could adversely affect the issuer's ability to record,
      process, summarize and report financial data and have identified for the
      issuer's auditors any material weaknesses in internal controls; and

      (b) Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the issuer's internal controls;
      and

                                       3


6. The issuer's other certifying officers and I have indicated in this quarterly
report whether or not there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date:  August 13, 2004

      /s/ Hal Sternberg
      -------------------------------------------
      Hal Sternberg
      Vice-President - Research
      Member, Office of the President*

* The Office of the President is comprised of the three executive officers of
the issuer who collectively exercise the powers of the Chief Executive Officer

                                       4



                                 CERTIFICATIONS

I, Harold Waitz, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioTime, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the issuer as of,
and for, the periods presented in this report;

4. The issuer's other certifying officers and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rule 13a-14(c)) for the issuer and have:

      (a) Designed such disclosure controls and procedures to ensure that
      material information relating to the issuer, including its consolidated
      subsidiaries, is made known to us by others within those entities,
      particularly during the period in which the periodic reports are being
      prepared;

      (b) Evaluated the effectiveness of the issuer's disclosure controls and
      procedures as of a date within 90 days prior to the filing date of this
      quarterly report (the "Evaluation Date"); and

      (c) Presented in this report our conclusions about the effectiveness of
      the disclosure controls and procedures based on our evaluation as of the
      Evaluation Date;

5. The issuer's other certifying officers and I have disclosed, based on our
most recent evaluation, to the issuer's auditors and the audit committee of
issuer's board of directors (or persons performing the equivalent functions):

      (a) All significant deficiencies in the design or operation of internal
      controls which could adversely affect the issuer's ability to record,
      process, summarize and report financial data and have identified for the
      issuer's auditors any material weaknesses in internal controls; and

      (b) Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the issuer's internal controls;
      and

                                       5


6. The issuer's other certifying officers and I have indicated in this quarterly
report whether or not there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date:  August 13, 2004

      /s/ Harold Waitz
      ------------------------------------------
      Harold Waitz
      Vice-President - Regulatory Affairs
      Member, Office of the President*

* The Office of the President is comprised of the three executive officers of
the issuer who collectively exercise the powers of the Chief Executive Officer

                                       6



                                 CERTIFICATIONS

I, Steven A. Seinberg, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioTime, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the issuer as of,
and for, the periods presented in this report;

4. The issuer's other certifying officers and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rule 13a-14(c)) for the issuer and have:

      (a) Designed such disclosure controls and procedures to ensure that
      material information relating to the issuer, including its consolidated
      subsidiaries, is made known to us by others within those entities,
      particularly during the period in which the periodic reports are being
      prepared;

      (b) Evaluated the effectiveness of the issuer's disclosure controls and
      procedures as of a date within 90 days prior to the filing date of this
      quarterly report (the "Evaluation Date"); and

      (c) Presented in this report our conclusions about the effectiveness of
      the disclosure controls and procedures based on our evaluation as of the
      Evaluation Date;

5. The issuer's other certifying officers and I have disclosed, based on our
most recent evaluation, to the issuer's auditors and the audit committee of
issuer's board of directors (or persons performing the equivalent functions):

      (a) All significant deficiencies in the design or operation of internal
      controls which could adversely affect the issuer's ability to record,
      process, summarize and report financial data and have identified for the
      issuer's auditors any material weaknesses in internal controls; and

      (b) Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the issuer's internal controls;
      and

                                       7


6. The issuer's other certifying officers and I have indicated in this quarterly
report whether or not there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date:  August 13, 2004

      /s/ Steven A. Seinberg
      --------------------------------------
      Steven A. Seinberg
      Chief Financial Officer

                                       8